Key result
The activity of serotonin receptors, the serotonin transporter, and Tph1 can be elevated in clinical and experimental PAH, offering potentially unique therapeutic targets.
The serotonin pathway, including serotonin receptors, SERT, and Tph1, represents a potential therapeutic target in pulmonary arterial hypertension.
Answers are grounded in this paper and cite their sources.
Serotonin pathway inhibition in PAH requires prospective validation; leaves open whether targeting receptors, transporter, or Tph1 improves outcomes.
In the 1960s, serotonin (5HT) was associated with pulmonary arterial hypertension (PAH) caused by certain diet pills, but has recently been the subject of renewed interest in the field of PAH. Serotonin can be synthesised in the pulmonary endothelium with the rate-limiting step being the activity of tryptophan hydroxylase1 (Tph1). The serotonin is released and can then: (i) pass into the underlying pulmonary smooth muscle cells through the serotonin transporter (SERT) to initiate proliferation and/or (ii) activate serotonin receptors on pulmonary smooth muscle cells to evoke proliferation and/or contraction. Serotonin may also mediate pulmonary fibroblast proliferation via the SERT and/or serotonin receptors. Here we will unravel, discuss and update the 'serotonin hypothesis' of PAH in light of recent advances in the field. In conclusion, the activity of serotonin receptors, the SERT and Tph1 can all be elevated in clinical and experimental PAH and each offers a potentially unique therapeutic target.
No takes yet. Share an insight, caveat, or question.
Margaret R. MacLean (2007) conducted a review in Pulmonary arterial hypertension (PAH). The activity of serotonin receptors, the serotonin transporter, and Tph1 can be elevated in clinical and experimental PAH, offering potentially unique therapeutic targets.
Synapse has enriched 10 related papers. Consider them for comparative context: